According to a recently published report by Roots Analysis, the success of 14 approved antibody drug conjugates (ADCs) and a promising developmental pipeline is driving the antibody drug conjugate market growth
The global antibody drug conjugate market size was estimated at USD 7.7 billion in 2023 and is expected to reach over USD 23 billion by 2035, growing at a CAGR of 9.63% in the forecast period 2023-2035.
Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Additionally, chemotherapy and radiation therapy are associated with several side effects. Such treatment options usually destroy large populations of healthy and rapidly proliferating cells, along with the tumor cells. Their non-specific nature has severe detrimental effects on the patient’s quality of life. Therefore, there is an urgent unmet need of innovative and effective cancer treatments for patients with late-stage and refractory cancer. Amidst the widespread initiatives to develop more targeted anti-cancer therapies, antibody drug conjugates have emerged as a highly specific and potent option to eradicate tumor cells with minimal side effects. In the past few years, great strides have been made in the field of personalized medicine; targeted therapies, such as ADCs, are on the forefront of next generation technologies that are anticipated to revolutionize the cancer treatment landscape.
Browse 285+ figures and 350+ market data tables spread across 715+ pages and detailed Table of Content on “Antibody Drug Conjugate Market by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” here: https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.html
Several factors are fueling antibody drug conjugate market growth. Due to their improved safety profiles, antibody drug conjugates have established themselves as a viable and effective alternative to traditional chemotherapy drugs that were used for the treatment of cancer. Recent advances in biotechnology have led to the introduction of site-specific conjugation technologies. These next (second and third) generation technology platforms have facilitated the development of homogenous mixtures of antibody drug conjugate molecules, which have defined drug-antibody ratios (DARs). Driven by the success of 14 approved antibody drug conjugates (ADCs) and a promising developmental pipeline, the field of ADCs has gained significant traction and are anticipated to capture a notable share of the cancer therapy market.
While the antibody drug conjugate market is experiencing substantial growth, it is not without its challenges. One of the primary restraints is the technical complexities associated with product development. Despite the fact that there are 14 approved products in the market, there are several parameters, such as antibody drug conjugates internalization and drug load optimization, that are still not understood clearly. Antibody drug conjugate development and supply chain are highly complex and fragmented, involving multiple stakeholders. Further, very few CMOs presently offer end-to-end services. As a result, there is an evident need for separate components of antibody drug conjugates to be frequently transported from one vendor site to another, across the manufacturing process.
Despite the challenges, several companies are exploring novel technologies and are investing heavily in the development of unique and effective antibody drug conjugate candidates. The increasing research activity in the industry is complemented by the rising interest of several academic institutes in this domain. Research efforts led by non-industry players have received a significant amount of financing in the form of grants. In the past decade, several institutes have been awarded more than 250 grants to support research projects in this domain. In fact, in 2022, more than 30 grants have already been awarded. Based on prevalent trends we are led to believe that in the near future, the ongoing research in academic institutes is likely to play a prominent role in driving innovation in this domain. Given the extensive R&D efforts and commercialization of multiple antibody drug conjugates, these therapeutic modalities are anticipated to carve out a significant share of the cancer therapy market.
Based on the type of target indication, the market is segmented into Acute Lymphoblastic Leukemia, Breast Cancer, Lung Cancer and Other Indications.
Based on the therapeutic area, the market is segmented into Hematological Cancer and Solid Tumors.
Based on the linker, the market is segmented into Valine-citrulline, Maleimidocaproyl and Others.
Based on the Payload, the market is segmented into Monomethyl auristatin E (MMAE), Duocarmycin, DM4 and Others.
Based on the Target Antigen, the market is segmented into HER-2, TROP-2, CEACAM5 and Others.
Based on the Regional Insights, the market is segmented into North America, Europe, and Asia Pacific
The antibody drug conjugate market report also includes detailed profiles of key players (listed below) that develop antibody drug conjugates:
You Can Download Free Sample PDF Copy of This Report at:
https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market-5th-edition-2019-2030/request-sample.html
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
